Chronic  ||| S:0 E:8 ||| JJ
migraine ||| S:8 E:16 ||| NN
:  ||| S:16 E:18 ||| :
treatment  ||| S:18 E:28 ||| NN
We  ||| S:28 E:31 ||| PRP
define  ||| S:31 E:38 ||| VB
chronic  ||| S:38 E:46 ||| JJ
migraine  ||| S:46 E:55 ||| NN
as  ||| S:55 E:58 ||| IN
that  ||| S:58 E:63 ||| DT
clinical  ||| S:63 E:72 ||| JJ
situation  ||| S:72 E:82 ||| NN
in  ||| S:82 E:85 ||| IN
which  ||| S:85 E:91 ||| WDT
migraine  ||| S:91 E:100 ||| VBP
attacks  ||| S:100 E:108 ||| NNS
appear  ||| S:108 E:115 ||| VBP
15  ||| S:115 E:118 ||| CD
or  ||| S:118 E:121 ||| CC
more  ||| S:121 E:126 ||| JJR
days  ||| S:126 E:131 ||| NNS
per  ||| S:131 E:135 ||| IN
month ||| S:135 E:140 ||| NN
.  ||| S:140 E:142 ||| .
Until  ||| S:142 E:148 ||| IN
recently ||| S:148 E:156 ||| RB
,  ||| S:156 E:158 ||| ,
and  ||| S:158 E:162 ||| CC
in  ||| S:162 E:165 ||| IN
spite  ||| S:165 E:171 ||| NN
of  ||| S:171 E:174 ||| IN
its  ||| S:174 E:178 ||| PRP$
negative  ||| S:178 E:187 ||| JJ
impact ||| S:187 E:193 ||| NN
,  ||| S:193 E:195 ||| ,
patients  ||| S:195 E:204 ||| NNS
with  ||| S:204 E:209 ||| IN
chronic  ||| S:209 E:217 ||| JJ
migraine  ||| S:217 E:226 ||| NN
were  ||| S:226 E:231 ||| VBD
excluded  ||| S:231 E:240 ||| VBN
of  ||| S:240 E:243 ||| IN
the  ||| S:243 E:247 ||| DT
clinical  ||| S:247 E:256 ||| JJ
trials ||| S:256 E:262 ||| NNS
.  ||| S:262 E:264 ||| .
This  ||| S:264 E:269 ||| DT
manuscript  ||| S:269 E:280 ||| NN
revises  ||| S:280 E:288 ||| VBD
the  ||| S:288 E:292 ||| DT
current  ||| S:292 E:300 ||| JJ
treatment  ||| S:300 E:310 ||| NN
of  ||| S:310 E:313 ||| IN
chronic  ||| S:313 E:321 ||| JJ
migraine ||| S:321 E:329 ||| NN
.  ||| S:329 E:331 ||| .
The  ||| S:331 E:335 ||| DT
first  ||| S:335 E:341 ||| JJ
step  ||| S:341 E:346 ||| NN
should  ||| S:346 E:353 ||| MD
include  ||| S:353 E:361 ||| VB
the  ||| S:361 E:365 ||| DT
avoidance  ||| S:365 E:375 ||| NN
of  ||| S:375 E:378 ||| IN
potential  ||| S:378 E:388 ||| JJ
precipitating ||| S:388 E:401 ||| NNS
/ ||| S:401 E:402 ||| VBP
aggravating  ||| S:402 E:414 ||| VBG
factors  ||| S:414 E:422 ||| NNS
for  ||| S:422 E:426 ||| IN
chronic  ||| S:426 E:434 ||| JJ
migraine ||| S:434 E:442 ||| NN
,  ||| S:442 E:444 ||| ,
mainly  ||| S:444 E:451 ||| RB
analgesic  ||| S:451 E:461 ||| JJ
overuse  ||| S:461 E:469 ||| NN
and  ||| S:469 E:473 ||| CC
the  ||| S:473 E:477 ||| DT
treatment  ||| S:477 E:487 ||| NN
of  ||| S:487 E:490 ||| IN
comorbid  ||| S:490 E:499 ||| JJ
disorders ||| S:499 E:508 ||| NNS
,  ||| S:508 E:510 ||| ,
such  ||| S:510 E:515 ||| JJ
as  ||| S:515 E:518 ||| IN
anxiety  ||| S:518 E:526 ||| NN
and  ||| S:526 E:530 ||| CC
depression ||| S:530 E:540 ||| NN
.  ||| S:540 E:542 ||| .
The  ||| S:542 E:546 ||| DT
symptomatic  ||| S:546 E:558 ||| JJ
treatment  ||| S:558 E:568 ||| NN
should  ||| S:568 E:575 ||| MD
be  ||| S:575 E:578 ||| VB
based  ||| S:578 E:584 ||| VBN
on  ||| S:584 E:587 ||| IN
the  ||| S:587 E:591 ||| DT
use  ||| S:591 E:595 ||| NN
of  ||| S:595 E:598 ||| IN
nonsteroidal  ||| S:598 E:611 ||| JJ
anti-inflammatory  ||| S:611 E:629 ||| JJ
agents  ||| S:629 E:636 ||| NNS
and  ||| S:636 E:640 ||| CC
triptans  ||| S:640 E:649 ||| NNS
( ||| S:649 E:650 ||| -LRB-
in  ||| S:650 E:653 ||| IN
this  ||| S:653 E:658 ||| DT
case  ||| S:658 E:663 ||| NN
< ||| S:663 E:665 ||| SYM
10  ||| S:665 E:668 ||| CD
days  ||| S:668 E:673 ||| NNS
per  ||| S:673 E:677 ||| IN
month ||| S:677 E:682 ||| NN
) ||| S:682 E:683 ||| -RRB-
.  ||| S:683 E:685 ||| .
It  ||| S:685 E:688 ||| PRP
is  ||| S:688 E:691 ||| VBZ
necessary  ||| S:691 E:701 ||| JJ
to  ||| S:701 E:704 ||| TO
avoid  ||| S:704 E:710 ||| VB
the  ||| S:710 E:714 ||| DT
use  ||| S:714 E:718 ||| NN
of  ||| S:718 E:721 ||| IN
combined  ||| S:721 E:730 ||| JJ
analgesics ||| S:730 E:740 ||| NN
,  ||| S:740 E:742 ||| ,
opioids  ||| S:742 E:750 ||| NN
and  ||| S:750 E:754 ||| CC
ergotamine-containing  ||| S:754 E:776 ||| JJ
medications ||| S:776 E:787 ||| NN
.  ||| S:787 E:789 ||| .
Preventive  ||| S:789 E:800 ||| JJ
treatment  ||| S:800 E:810 ||| NN
includes  ||| S:810 E:819 ||| VBZ
a  ||| S:819 E:821 ||| DT
' ||| S:821 E:822 ||| POS
transitional ||| S:822 E:834 ||| NN
'  ||| S:834 E:836 ||| POS
treatment  ||| S:836 E:846 ||| NN
with  ||| S:846 E:851 ||| IN
nonsteroidal  ||| S:851 E:864 ||| JJ
anti-inflammatory  ||| S:864 E:882 ||| JJ
agents  ||| S:882 E:889 ||| NNS
or  ||| S:889 E:892 ||| CC
steroids ||| S:892 E:900 ||| NNS
,  ||| S:900 E:902 ||| ,
while  ||| S:902 E:908 ||| IN
preventive  ||| S:908 E:919 ||| JJ
treatment  ||| S:919 E:929 ||| NN
exerts  ||| S:929 E:936 ||| VBD
its  ||| S:936 E:940 ||| PRP$
actions ||| S:940 E:947 ||| NNS
.  ||| S:947 E:949 ||| .
Even  ||| S:949 E:954 ||| RB
though  ||| S:954 E:961 ||| IN
those  ||| S:961 E:967 ||| DT
medications  ||| S:967 E:979 ||| JJ
efficacious  ||| S:979 E:991 ||| NN
in  ||| S:991 E:994 ||| IN
episodic  ||| S:994 E:1003 ||| JJ
migraine  ||| S:1003 E:1012 ||| JJ
prevention  ||| S:1012 E:1023 ||| NNS
are  ||| S:1023 E:1027 ||| VBP
used ||| S:1027 E:1031 ||| VBN
,  ||| S:1031 E:1033 ||| ,
the  ||| S:1033 E:1037 ||| DT
only  ||| S:1037 E:1042 ||| JJ
drugs  ||| S:1042 E:1048 ||| NNS
with  ||| S:1048 E:1053 ||| IN
demonstrated  ||| S:1053 E:1066 ||| JJ
efficacy  ||| S:1066 E:1075 ||| NN
in  ||| S:1075 E:1078 ||| IN
the  ||| S:1078 E:1082 ||| DT
preventive  ||| S:1082 E:1093 ||| JJ
treatment  ||| S:1093 E:1103 ||| NN
of  ||| S:1103 E:1106 ||| IN
chronic  ||| S:1106 E:1114 ||| JJ
migraine  ||| S:1114 E:1123 ||| NNS
are  ||| S:1123 E:1127 ||| VBP
topiramate  ||| S:1127 E:1138 ||| VBN
and  ||| S:1138 E:1142 ||| CC
pericranial  ||| S:1142 E:1154 ||| JJ
infiltrations  ||| S:1154 E:1168 ||| NN
of  ||| S:1168 E:1171 ||| IN
Onabotulinumtoxin  ||| S:1171 E:1189 ||| NNP
A ||| S:1189 E:1190 ||| NNP
.  ||| S:1190 E:1192 ||| .
